大象传媒

I am a clinical hematologist with an academic focus and national leadership role in the field of vascular anomalies. I built and co-directed the Vascular Anomalies Program at Vanderbilt University Medical Center and served as Associate Clinical Director of the Comprehensive Vascular Anomalies Program and Co-Director of the Pediatric Hereditary Hemorrhagic Telangiectasia Program at the Children鈥檚 Hospital of Philadelphia (CHOP) prior to transitioning to my current role as Co-Director of the 大象传媒 Vascular Anomalies Program. Through my various research collaborations and endeavors, I remain dedicated to advancing the care of people living with vascular malformations and tumors. I serve as Chair of the Research Committee for vascular anomalies through the American Society of Pediatric Hematology-Oncology (ASPHO), I led a multicenter study evaluating treatment regimens and risk factors in Kaposiform hemangioendothelioma (KHE), a rare vascular tumor, and I am PI for the trametinib arm of the Vascular Anomalies Therapeutic Choice (VATCH) trial through our Consortium for the Investigators of Vascular Anomalies (CaNVAS). I collaborate on multiple national research projects and have served as site-PI on several industry sponsored studies in hematology and vascular anomalies. I have been invited to speak nationally and internationally on medical therapies in vascular anomalies. My career is dedicated to improving the lives of children and families with vascular anomalies.